Skip to main content

CA209-73L A Phase 3, Randomized, Open Label Study to Compare Nivolumab plus Concurrent Chemoradiotherapy (CCRT) followed by Nivolumab plus Ipilimumab or Nivolumab plus CCRT Followed by Nivolumab vs CCRT followed by Duravalumab in Previously Untreated, Loc

NCT04026412

A Phase 3, Randomized, Open Label Study to Compare Nivolumab plus Concurrent Chemoradiotherapy (CCRT) followed by Nivolumab plus Ipilimumab or Nivolumab plus CCRT Followed by Nivolumab vs CCRT followed by Duravalumab in Previously Untreated, Locally Advanced Non-small Cell Lung Cancer (LA NSCLC)

Associated Conditions

Lung Cancer

Principal Investigator

Sponsor

Bristol-Myers Squibb

The purpose of this study is to evaluate the effectiveness (how well the drug(s) work), safety, and tolerability of adding the investigational drug, Nivolumab, to concurrent chemoradiotherapy followed by treatment with Nivolumab and Ipilimumab or Nivolumab alone, in participants with stage 3, locally advanced non-small cell lung cancer (LA NSCLC). Participants in the control group will receive
concurrent chemoradiotherapy followed by treatment with Durvalumab.

This study is currently enrolling.